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Abstract
Peritoneal dialysis (PD) is complicated by peritonitis episodes that cause loss of mesothelium and eventually sclerosing
peritonitis. An improved understanding of the molecular contributors to peritoneal injury and defense may increase the
therapeutic armamentarium to optimize peritoneal defenses while minimizing peritoneal injury. There is no information on
the expression and function of the cytokine TWEAK and its receptor Fn14 during peritoneal injury. Fn14 expression and
soluble TWEAK levels were measured in human PD peritoneal effluent cells or fluids with or without peritonitis. Fn14
expression was also analyzed in peritoneal biopsies from PD patients. Actions of intraperitoneal TWEAK were studied in
mice in vivo. sTWEAK levels were increased in peritoneal effluent in PD peritonitis. Effluent sTWEAK levels correlated with
the number of peritoneal macrophages (r = 0.491, p = 0.002). Potential TWEAK targets that express the receptor Fn14
include mesothelial cells and macrophages, as demonstrated by flow cytometry of peritoneal effluents and by analysis of
peritoneal biopsies. Peritoneal biopsy Fn14 correlated with mesothelial injury, fibrosis and inflammation, suggesting a
potential deleterious effect of TWEAK/Fn14. In this regard, intraperitoneal TWEAK administration to mice promoted
peritoneal inflammation characterized by increased peritoneal effluent MCP-1, Fn14 and Gr1+ macrophages, increased
mesothelial Fn14, MCP-1 and CCL21 expression and submesothelial tissue macrophage recruitment. Taken together these
data suggest that the TWEAK/Fn14 system may promote inflammation and tissue injury during peritonitis and PD.
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Introduction
Peritonitis is a potentially devastating disease occurring in the
context of abdominal visceral injury, cirrhosis, peritoneal dialysis
(PD) and others. PD is a renal replacement therapy modality that
is marred by episodes of bacterial infection, leading to localized
inflammation evidenced as peritonitis [1]. Moreover, dialysis
solutions can themselves induce sterile peritoneal inflammation
[2,3]. PD represents an interesting human model of inflammation
since the technique allows repeated non-invasive access to the
peritoneal cavity, allowing both monitoring of the inflammatory
process as well as therapy by local delivery of drugs [4]. Peritoneal
inflammation is characterized by local upregulation of several
cytokines, macrophage recruitment, and collagen synthesis by
mesothelial cells and fibroblasts leading to loss of peritoneal
membrane integrity and fibrosis. Both acute and chronic
peritoneal inflammation may lead to PD technique failure [5].
In some cases PD-associated chronic peritoneal inflammation may
result in sclerosing peritonitis [6]. Sclerosing peritonitis is a fatal
form of peritoneal inflammation characterized by a fibrous
thickening of the peritoneum. Understanding the role of the
different players involved may help design strategies to limit
inflammation-mediated tissue injury without compromising anti-
bacterial defenses.
Tumor necrosis factor-like weak inducer of apoptosis (TWEAK,
TNFSF12) is a member of the TNF superfamily of structurally-
related cytokines. TWEAK may modulate cell death, proliferation,
inflammation and angiogenesis [7–10]. Fibroblast growth factor-
inducible 14 (Fn14) is the functional TWEAK receptor. Fn14
expression is strongly induced during tissue injury, repair and
remodeling [11]. Cells can express full-length membrane-
anchored TWEAK (mTWEAK) and secrete a soluble form
(sTWEAK), and both bind and activate Fn14 [11]. sTWEAK
levels in serum/plasma or urine may have biomarker value in
inflammatory diseases, such as atherosclerosis, lupus nephritis and
chronic kidney disease [12–14]. The role of TWEAK in
inflammation has been described in the central nervous system,
cardiovascular injury and kidney disease [15–20], but there is no
information on the expression and role of TWEAK and Fn14
during human infection or peritoneal inflammation.
We have now explored the expression of TWEAK and Fn14
during human peritoneal infection and in vivo effects of TWEAK
on peritoneal inflammation. We report that sTWEAK levels are
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increased in effluents from PD patients with peritonitis and
correlate with effluent macrophage number. Fn14 expression is
also increased in cells from peritonitis effluents and local tissue
Fn14 expression correlates with mesothelial injury in human
peritoneal biopsies. Finally, intraperitoneal TWEAK injection in
mice promotes peritoneal inflammation and increases macrophag-
es in peritoneal effluents and in the peritoneal tissue. These results
support a role of TWEAK in peritoneal injury and inflammatory
cell recruitment and suggest that TWEAK may be a biomarker of
peritoneal inflammation during PD.
Materials and Methods
Human samples
Human samples were obtained following a protocol approved
by the IDIPAZ Ethics Committee and informed consent was
obtained. Peritoneal effluent samples were obtained from patients
undergoing chronic PD in the course of a peritonitis episode
(n = 14) or from stable PD patients without peritonitis in the prior
3 months and without any other cause systemic inflammation
(Non-peritonitis group; n = 8). The characteristics of study
participants are presented in Tables 1 and 2. Human
peritoneum biopsy samples were obtained at the time of
transplantation or abdominal surgery from 9 patients without
evidence of systemic inflammation (Table 3). PD patients were
stable at the time of biopsy, with no recent peritonitis. An
experienced pathologist (JJH) scored the biopsies blinded as to the
nature of the sample and following a previously established
peritoneal injury score. This score assesses 3 items (mesothelial
integrity, peritoneal fibrosis and peritoneal inflammation) in a 0–3
scale for a total possible maximum score of 9 for most severely
injured samples [21]. In this regard, in the present manuscript, the
published score was modified in order to assign a score of 3 (rather
than 0) to the most severe mesothelial injury (loss of mesothelium)
and a score of 0 (rather than 3) to mesothelial integrity.
ELISA
sTWEAK levels in human peritoneal effluent were determined
with a commercially available enzyme-linked immunosorbent
assay (ELISA) kit (BMS2006INST; Bender MedSystems, Vienna,
Austria). MCP-1 levels in murine peritoneal lavages were
measured by commercial ELISA (BD Pharmingen, NJ).
Table 2. Clinical characteristics of stable PD patients without
peritonitis in the prior 3 months providing peritoneal effluent
samples.
Patient Age Sex Cause of ESRD
1 30 Female Vasculitis
2 30 Female Unknown
3 60 Female Polycystic kidneys
4 57 Male Nephroangiosclerosis
5 76 Male Diabetes type II
6 58 Female Interstitial
7 29 Male Glomerulonephritis
8 29 Male Glomerulonephritis
ESRD: End-stage renal disease.
doi:10.1371/journal.pone.0090399.t002
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Mesothelial cell cultures
The study was approved by the clinical ethics committee of IIS-
Fundacio´n Jime´nez Dı´az and written informed consent was
obtained. Human omental mesothelial cells (HOMC) were
obtained from omentum from 6 non-PD patients who underwent
unrelated elective abdominal surgery [22,23].
Western blot
Cell samples were homogenized in lysis buffer (50 mM
TrisHCl, 150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 0.2%
Triton X-100, 0.3% NP-40, 0.1 mM PMSF and 1 mg/ml
pepstatin A) then separated by 12% SDS-PAGE under reducing
conditions [20]. After electrophoresis, samples were transferred to
PVDF membranes (Millipore), blocked with 5% skimmed milk in
PBS/0.5% v/v Tween 20 for 1 hr, washed with PBS/Tween, and
Figure 1. Increased peritoneal effluent sTWEAK in PD peritonitis. A) sTWEAK levels were measured in peritoneal effluents from PD patients
with peritonitis (days 1 and 461) or without peritonitis. Clinical data in tables 1 and 2. *p,0.002 vs non-peritonitis. B) Evolution of sTWEAK levels
through the peritonitis episode in 6 individual patients with at least three samples that cover the whole peritonitis episode. sTWEAK levels decrease
when peritonitis resolves. Peritonitis episodes correspond to those presented in table 1. C) Scatter plot showing the significant positive correlation
between sTWEAK levels and the number of peritoneal macrophages in peritoneal effluents during 17 episodes of peritonitis in PD patients.
doi:10.1371/journal.pone.0090399.g001
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incubated with rabbit polyclonal anti-Fn14 (1:1000, Cell Signal-
ing, Danvers, MA) and rabbit polyclonal anti-TWEAK (1:500,
Santa Cruz Biotechnology, Santa Cruz, CA) diluted in 5% BSA.
Blots were washed with PBS/Tween and incubated with
appropriate horseradish peroxidase-conjugated secondary anti-
body (1:2000, Amersham, Aylesbury, UK). After washing with
PBS/Tween blots were developed with the chemiluminescence
method (ECL) (Amersham). Blots were then probed with mouse
monoclonal anti-a-tubulin antibody (1:2000, Sigma) and levels of
expression were corrected for minor differences in loading.
Fn14 immunofluorescence colocalization in human
peritoneum biopsies
The general procedures have been previously described [24].
Antigenic epitope retrieval was performed in 3 mm thick sections
of paraffin-embedded tissue using a PTlink device (with a high pH
solution, 95uC, 20 min). Tissue slides were incubated overnight at
Figure 2. Fn14 is expressed by cultured human mesothelial cells and by leukocytes in peritoneal effluents from PD patients. A)
Cultured human mesothelial cells (HMC) express Fn14 and TWEAK as assessed by western blot. Representative images of three different experiments.
B) Fn14 expression was analyzed by flow cytometry in peripheral blood and peritoneal effluent leucocytes. Cells were stained with Fn14-PE and
monocyte/macrophages, T cells and NK cells were identified with anti-CD14, anti-CD3 and anti-CD56 antibodies respectively within the appropriate
gates according to FSC and SSC parameters. Controls for the technique were stained with isotype immunoglubulin. Peripheral blood mononuclear
cells (PBMCs) were used as positive controls for leukocyte population markers. Numbers within histograms indicate mean fluorescence intensity (MFI)
for Fn14 staining. Note increased Fn14 expression mainly in peritoneal macrophages from patients with peritonitis.
doi:10.1371/journal.pone.0090399.g002
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4uC with the primary antibodies, rabbit polyclonal anti-Fn14
(1:100, Cell Signaling) and mouse monoclonal anti-cytokeratin 8
(1:60, Santa Cruz Biotechnology) or mouse monoclonal anti-
CD68 (Dako Diagnostics, Barcelona, Spain). Slides were then
washed with PBS and incubated with anti-rabbit Alexa488 and
anti-mouse Alexa 633 conjugated secondary antibodies (1:300,
Invitrogen, Carlsbad, CA).
Fn14 immunohistochemistry
In human peritoneum biopsies antigenic epitope retrieval was
performed in 3 mm thick sections of paraffin-embedded tissue
using a PTlink device (with a high pH solution, 95uC, 20 min).
Endogenous peroxidase was blocked by incubation in 3% H2O2/
methanol (1:1) at 25uC for 30 minutes [25]. Slides were incubated
in PBS with 4% bovine serum albumin (BSA) and 1% horse
serum, for 1 hour at 37uC to reduce nonspecific background
staining, and then incubated overnight at 4uC with rabbit
polyclonal anti-Fn14 (1:100, Cell Signaling) in PBS, 4% BSA,
1% serum. After washing with PBS, sections were incubated with a
secondary biotin-labeled antibody, washed and developed with AB
streptavidin-complex. Finally, sections were washed and stained
with DAB (Dako Diagnostics). Sections were counterstained with
Carazzi’s hematoxylin. Negative controls included incubation with
isotype IgG. Fn14 staining was evaluated by a quantitative scoring
system, Image-Pro Plus software (Media cybernetics, MD) in 12
randomly selected fields (x20) per sample by an observer blinded
as to eh nature of the samples.
In murine samples antigenic epitope retrieval was performed in
5 mm thick sections of paraffin-embedded tissue using a PTlink
device (with a high pH solution, 95uC, 20 min). Tissue slices were
incubated for 30 min at room temperature with the primary
antibody, rabbit polyclonal anti-Fn14 (1:100, Cell Signaling), goat
polyclonal anti-MCP-1 (1:500, Santa Cruz), goat polyclonal anti-
CCL21 (1:150, R&D Systems, Minneapolis, MN) and rat
polyclonal anti-F4/80 (1:10000, Serotec) [20]. For immunohisto-
chemical staining Envision FLEX + visualization system was used,
in a DAKO Autostainerplus platform. Tissue sections were
subsequently counterstained with hematoxylin. Same sections
were incubated without the primary antibody as negative controls.
Animal model
Studies were conducted in accord with the NIH Guide for the
Care and Use of Laboratory Animals. C57BL6 female mice (12- to
14-week-old) (IFFA-CREDO, Barcelona, Spain) received
0.75 mg/human recombinant TWEAK (Millipore, Billerica, MA)
or saline (n = 5 per group) intraperitoneally. Mice were killed 4 h
or 24 h after injection. The dose of TWEAK was calculated based
on in vitro experiments for an extracellular volume of 7.5 ml/
mouse [19].The dose had been validated in prior animal
experiments, where the time course of systemic TWEAK actions
were explored with focus on the kidney. To determine peritoneal
production of chemokines, the peritoneal cavity was lavaged with
two ml saline immediately after mice were euthanised. The
solution (murine peritoneal lavage) was centrifuged and the
supernatant was separated into small aliquots and stored at
280uC and the pellet containing cells was used for flow cytometry
analysis and for RT-PCR. After sacrifice parietal peritoneum was
collected, fixed in neutral-buffered formalin and embedded in
paraffin [26].
Flow cytometry
Human peripheral blood mononuclear cells, human peritoneal
effluent cells and murine peritoneal effluent cells were analyzed by
flow cytometry.
Figure 3. Colocalization of Fn14 and mesothelial cell markers
in human preserved peritoneum. Human non-infected peritoneum
from stable chronic PD patient with preserved mesothelium was
stained with both anti-Fn14 antibody (green) and anti-cytokeratin 8
antibody (red). Mesothelial cells (red) express Fn14 (green). Confocal
microscopy. Original magnification x200, detail x400 and x1000.
doi:10.1371/journal.pone.0090399.g003
Figure 4. CD68 positive macrophages express Fn14 in human
injured peritoneum. Human peritoneum biopsies from non-infected,
stable, chronic PD patients were stained with both anti-Fn14 antibody
(green) and anti-CD68 antibody (red). CD68+ macrophages (red) are
among the submesothelial cells that express Fn14 (green)(white
arrows). Additional submesothelial cells express Fn14 (arrowhead).
Confocal microscopy. Original magnification x200, detail x400 and
x1000.
doi:10.1371/journal.pone.0090399.g004
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Cells were isolated from PD effluents by centrifugation at 500 g
for 159 at 4uC. PBMCs from healthy control donors were prepared
by Ficoll-Hypaque (Amersham Pharmacia Biotech, Sweden)
density gradient centrifugation. The following mAb were used
for flow cytometry analysis of surface molecules: CD3-PerCP,
CD14-FITC, CD56-APC (BD Biosciences) and Fn14-PE
(eBioscience). Cells were pre-incubated with 50 mg/mL human
IgG to prevent binding to FcR and stained according to standard
protocols. Analysis was performed in a FACScalibur cytometer
with ProQuest software (BD Bioscience).
Cells from murine peritoneal effluent were analyzed by flow
cytometry using the following antibodies: anti-mouse CD4 PE and
Alexa FluorH 488-labelled anti-mouse CD8a for T cells. F4/80
PE-Cy7, Gr1 APC, CD14 FITC and CD11b PE for macrophages
(BD Biosciences, San Diego, USA). Macrophages were defined as
CD11b+F4/80+ cells and Gr1+ macrophages as CD11b+F4/
80+Gr1+ cells. Neutrophils were defined as Gr1+/F4/80- cells.
RNA extraction and Real-Time Polymerase Chain
Reaction
Total RNA was extracted from cells and tissue by the TRI
Reagent method (Sigma) and 1 mg of RNA was reverse transcribed
with High Capacity cDNA Archive Kit (Applied Biosystems,
Foster City, CA). Pre-developed primer and probe assays for Fn14,
and GAPDH (human) were from Applied (Applied Biosystems).
Quantitative PCR was performed by 7500 Real Time PCR
Figure 5. Increased Fn14 protein expression in peritoneal biopsies from non-infected patients. A) Fn14 immunohistochemistry in
peritoneal tissue from non-infected, stable, chronic PD patients with different degrees of injury. Representative images from each group. Controls for
the technique are stained with nonspecific immunoglobulin (Ig (-)). B) Quantification of Fn14 protein expression in peritoneal biopsies from non-
infected patients. Fn14 staining was higher in patients with a more severe peritoneal histological injury score that evaluated mesothelial integrity,
peritoneal fibrosis and peritoneal inflammation (table 3)32. Mean 6 SEM *p,0.04, n = 4–5 patients per group.
doi:10.1371/journal.pone.0090399.g005
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System with the Prism 7000 System SDS Software (Applied
Biosystems) and RNA expression of different genes was corrected
for GAPDH [27].
Statistical analysis
Non-normally distributed variables were expressed as median
(interquartile range), and normally distributed variables were
expressed as mean 6 SEM. p,0.05 was considered to be
statistically significant. Mann–Whitney tests were used to compare
the results between two groups. Spearman rank correlation was
used to determine correlations between two variables. Statistical
analysis was performed with SPSS software package version 11.0.
Results
sTWEAK concentrations are increased in peritoneal
effluent from PD peritonitis
sTWEAK levels were measured in peritoneal effluents from PD
patients during and after peritonitis episodes. General character-
istic of the studied populations are summarized in tables 1 and 2.
Peritoneal effluent sTWEAK levels were increased in patients with
peritonitis between day 1 and day 461 compared with patients
without peritonitis (Figure 1.A). Moreover, peritoneal effluent
sTWEAK levels decreased when peritonitis was resolving
(Figure 1.B) and correlated with the number of peritoneal
effluent macrophages (Figure 1.C). However, no correlation was
found between sTWEAK and peritoneal effluent neutrophils,
indeed the number of peritoneal effluent neutrophils rapidly
decreases after initiation of antibiotic therapy in PD patients
(Figure S1).These data indicate that sTWEAK could be a
biomarker for severity of local inflammation in a model of human
infection, peritonitis. TNFa levels were undetectable in these
samples (not shown).
Fn14 is expressed by cultured human mesothelial cells
and by PD peritoneal effluent leukocytes
Fn14 is the only known signal-transducing TWEAK receptor.
Thus, we evaluated cell types potentially responsive to TWEAK
by assessing the expression of Fn14. Cultured human mesothelial
cells express Fn14 (Figure 2.A). Mesothelial cells may also be a
source of TWEAK (Figure 2.A). In addition, Fn14 expression is
increased in monocytes/macrophages (CD14+) present in perito-
neal effluents from PD patients with peritonitis compared to
patients without peritonitis (Figure 2.B). This result suggests that
mesothelial cells or monocytes/macrophages might be responsive
to TWEAK during peritonitis.
Increased Fn14 expression in peritoneal biopsies from
chronic PD patients
Next we checked whether the cell culture observation of Fn14
expression by mesothelial cells was relevant in vivo. We
immunolocalized Fn14 in peritoneal biopsies from subjects in
table 3. Fn14 colocalized with mesothelial cell markers in
peritoneal biopsies with preserved histological features, including
a preserved mesothelial monolayer (Figure 3), confirming the cell
culture observation that mesothelial cells express Fn14
(Figure 2.A). However, in human PD-induced peritoneal injury,
Fn14 colocalized with CD68 positive macrophages and was not
present in the demesothelized peritoneal membrane (Figure 4).
Additional submesothelial cell types also expressed Fn14.
Next, we quantified Fn14 expression in peritoneal biopsies.
Peritoneal tissue samples were classified by a histological
peritoneal injury score that quantified mesothelial integrity,
fibrosis and inflammation (Table 3). Histological tissue injury
was classified as mild (peritoneal injury score 0-2) or moderate-
severe (score 4–9). Local peritoneal Fn14 expression was increased
in patients with peritoneal injury (Figure 5). Fn14 expression
correlated with peritoneal injury score (a composite of mesothelial
integrity, peritoneal fibrosis and peritoneal inflammation), perito-
neal fibrosis and peritoneal inflammation (Figure 6).
Figure 6. Fn14 protein expression in peritoneal tissue corre-
lates with peritoneal injury, fibrosis and inflammation in
humans. Scatter plot showing the significant positive correlation
between Fn14 expression in peritoneal tissue from non-infected
patients (n = 9) and histological peritoneal injury, peritoneal fibrosis
and peritoneal inflammation scores.
doi:10.1371/journal.pone.0090399.g006
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Intraperitoneal TWEAK promotes peritoneal
inflammation in mice
The association between TWEAK/Fn14 expression and
inflammation in humans begets the question whether TWEAK
promotes inflammation or inflammation increases TWEAK. We
next explored TWEAK actions on the peritoneal effluent and the
peritoneal tissue in vivo. Intraperitoneal TWEAK administration
to mice increased peritoneal lavage monocyte chemotatic protein
1 (MCP-1) levels (Figure 7.A), peritoneal lavage cell expression of
MCP-1 and Fn14 mRNA (Figure 7.B), and the percentage of
Gr1+ macrophages, the murine equivalent to activated human
CD14+ macrophages that express the CCR2 receptor for MCP-1
[28] (Figure 7.C). Moreover, TWEAK mildly increased the
percentage of CD8+ cells (Figure 7.C) and neutrophils (Figure
S2). Changes in peritoneal cell distribution or chemokine levels
following a single TWEAK injection were observed at early time
points (4 hours) and had returned to baseline or were decreasing at
24 h. This time-course is consistent with previously described
time-courses of TWEAK or TNF-induced inflammation in other
organs such as the kidney [19].
TWEAK also increased peritoneal tissue Fn14 mRNA expres-
sion as assessed by quantitative RT-PCR (Figure 8.A). Immu-
nohistochemistry showed Fn14 expression in mesothelial cells and
Figure 7. TWEAK increases inflammatory mediators in murine peritoneal effluents. A) MCP-1 protein levels were quantified by ELISA in
peritoneal lavage of mice that had received intraperitoneal TWEAK or vehicle (control). Mean 6 SEM of 5 animals per group. *p,0.001 vs control. B)
MCP-1 and Fn14 mRNA levels measured in peritoneal lavage cells. Median (25th to 75th percentile) of 5 animals per group. *p,0.03. C) Quantification
by flow cytometry of inflammatory cells present in murine peritoneal lavage. Mean 6 SEM of 5 animals per group. *p,0.05. Macrophages were
defined as CD11b+F4/80+ cells and Gr1+ macrophages as CD11b+F4/80+Gr1+ cells.
doi:10.1371/journal.pone.0090399.g007
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in infiltrating submesothelial cells (Figure 8.B), as was the case for
human peritoneal biopsies (Figure 3, 4). TWEAK also increased
peritoneal tissue MCP-1 and CCL21 mRNA expression
(Figure 9). These chemokines were chosen for analysis because
they represent canonical and non-canonical NFKB activation by
TWEAK, respectively [29], and they are relevant for peritoneal
injury since MCP-1 attracts macrophages and CCL21 attracts
fibrocytes [30]. Upregulation of peritoneal tissue Fn14 and MCP-1
mRNA was observed earlier (4 hours) than CCL21 mRNA
upregulation (24 hours). This time course is similar to that
observed in the kidney of TWEAK-treated mice [19,20]. Likewise,
immunohistochemistry disclosed increased MCP-1 and CCL21
protein in peritoneal tissue of mice treated with TWEAK
(Figure 10). Mesothelial cells expressed the chemokines, indicat-
ing that these Fn14-expressing cells are key peritoneal responders
to TWEAK stimulation. Moreover, TWEAK promoted tissue
macrophage recruitment (Figure 10). Macrophage infiltration
was observed in the sub-mesothelial region, next to Fn14- and
chemokine-expressing mesothelial cells.
Discussion
The main findings are high sTWEAK levels in peritoneal
effluents during human peritonitis, a correlation of peritoneal
tissue Fn14 receptor expression with peritoneal injury in long-term
PD, and the observation that in vivo TWEAK activates Fn14-
Figure 8. TWEAK increases Fn14 expression in murine peritoneal tissue in vivo. A) Intraperitoneal TWEAK administration increased Fn14
mRNA in peritoneal tissue. Mean 6 SEM of 5 animals per group. *p,0.02. B) Fn14 immunohistochemistry. TWEAK administration increased Fn14
expression in mesothelial cells and submesothelial infiltrating cells (arrows). Controls for the technique are stained with nonspecific Ig (-). Images
representative of 5 animals per group.
doi:10.1371/journal.pone.0090399.g008
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expressing cells mesothelial cells and promotes peritoneal inflam-
mation in mice. These findings identify sTWEAK as a potential
biomarker and therapeutic target in peritoneal inflammation. This
observation may be of interest to other forms of bacterial
peritonitis and to chronic peritoneal injury associated with PD.
Moreover, the findings could apply to tissue injury in the course of
other human bacterial infections.
The nature of PD allows repeated non-invasive access to events
taking place in the peritoneal cavity. Thus, PD is a human model
which allows the monitoring of inflammatory events in vivo during
infection or in the long-term course of sterile inflammation.
Findings in the human PD model may be representative of events
in other conditions characterized by bacterial infection or sterile
inflammation and may guide the development of hypothesis and
studies on the role of specific molecules in these events. We have
taken advantage of this model to identify high levels of sTWEAK
in peritoneal effluents during peritonitis episodes and to study the
potential role of en excess of this cytokine in the peritoneal cavity.
While our study draws attention to the potential of sTWEAK as
a biomarker in peritoneal inflammation, the design does not allow
definition of a specific role of sTWEAK in monitoring of
peritoneal inflammation and in assessing potential outcomes that
might guide therapeutic decision-making regarding intensification
or change of antibiotic therapy or the decision to remove the
peritoneal catheter. However, further studies should address these
possibilities. A role in this respect may be envisioned since another
candidate indicator of the severity of inflammation, TNFa, could
not be detected in these samples. We did not address the sources of
peritoneal effluent sTWEAK in humans in vivo, but cell culture
results presented here and a literature review suggest that both
mesothelial cells and macrophages are potential sources [31].
Inflammation is a physiological response to bacterial aggression.
In the course of peritonitis multiple inflammatory mediators are
released locally [32–35]. For some of them functional evidence of
their link to tissue injury has been provided [23,36–40]. Thus,
TGFb1 promotes peritoneal fibrosis and dysfunction [37,39],
PDGF-B promotes angiogenesis [38], IL-6 and its soluble receptor
(sIL-6R) control the pattern of leukocyte recruitment during
peritoneal inflammation [40] and the IFNc/TNFa combination
promotes mesothelial cell apoptosis [23]. Indeed, a single episode
of very severe peritonitis may cause irreversible peritoneal fibrosis.
It is thus necessary to understand the different contributors to
peritoneal inflammation. Our results indicate that during perito-
neal inflammation mesothelial cells upregulate the TWEAK
receptor Fn14 and that TWEAK activates mesothelial cells to
promote the expression of chemokines dependent on both
canonical and non-canonical NFkB activation [19,20] to attract
macrophages into the peritoneal cavity and peritoneal tissue.
Although we did not specifically explore non-canonical vs
canonical NFkB activation in the present work, the time-course
of gene expression of the canonical NFkB target MCP-1 and of the
non-canonical NFkB target CCL21 observed in vivo in mice is
consistent with prior studies supporting the involvement of these
pathways in upregulation of these specific chemokines [20].
Indeed, the transient, self-limited nature of MCP-1 upregulation is
characteristic of canonical NFkB response elicited by a single
exposure to TWEAK or TNF [29]. Macrophages are the key
targets of the chemotactic activity of MCP-1. In this regard, the
observed increase in the percentage of Gr1+ peritoneal lavage
macrophages coinciding with peak MCP-1 levels is consistent with
the inflammatory nature of these macrophages. Gr1+ macrophag-
es express the MCP-1 receptor CCR2 and activate integrins,
increasing their ability to roll on endothelial cell and migrate into
inflamed tissue [41]. TWEAK may also directly activate macro-
phages, since Fn14 expression is upregulated in macrophages
during peritonitis. Among CCL21 targets, fibrocytes are of
particular interest. These are circulating fibroblast precursors that
are attracted by CCL21 and may contribute to peritoneal fibrosis
[30]. In this regard, Fn14 expression in human peritoneum
correlated with the peritoneal fibrosis score. In mice, intraperito-
neal TWEAK also transiently increased peritoneal lavag neutro-
phils, although the effect was milder than on macrophages. In this
regard, no correlation between peritoneal effluent sTWEAK and
macrophages was observed in human PD peritonitis, suggesting
that factors other than TWEAK are more important in recruiting
neutrophils or that neutrophil contribution to sTWEAK levels is
minor.
In several animal models TWEAK has consistently shown to
promote further inflammation and tissue injury during sterile
inflammation. This has been observed in kidney, vascular and
central nervous system disease [15–20,42,43]. The association
between Fn14 expression and histological peritoneal injury scores
in chronic, non-infected PD patients suggests that TWEAK may
also have such a role in long-term PD peritoneal injury. Current
ongoing clinical trials are testing the tissue protective action of
neutralizing anti-TWEAK antibodies during sterile inflammation
(http://clinicaltrials.gov/show/NCT00771329, accessed on
March 23, 2013, http://clinicaltrials.gov/ct2/show/
NCT01499355, accessed on October 23, 2013). The results of
these trials will guide the potential evaluation of this therapeutic
tool in the PD context. In this regard, TWEAK has additional
actions of potential relevance for peritoneal injury which we have
not addressed. Thus, TWEAK has a pro-angiogenic role and
angiogenesis has been associated with peritoneal dysfunction.
However, the role of TWEAK/Fn14 during infection has not been
adequately characterized. A potential contribution of sTWEAK to
Figure 9. TWEAK promotes murine peritoneal tissue chemo-
kine mRNA expression in vivo. MCP-1 and CCL21 mRNA levels
measured by RT-PCR in murine peritoneal tissue 4 and 24 hours
following TWEAK administration. Median (25th to75th percentile) of 5
animals per group. *p,0.05.
doi:10.1371/journal.pone.0090399.g009
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peritoneal defense during acute peritonitis, probably by favoring
leukocyte recruitment, cannot be excluded.
In conclusion, TWEAK and its receptor are highly expressed in
the peritoneum under diverse pathological circumstances and they
promote inflammation. Further studies are needed to explore the
biomarker and therapeutic potential of these findings.
Supporting Information
Figure S1 Human peritoneal effluent sTWEAK levels do
not correlate with peritoneal effluent neutrophils. A)
Neutrophil counts rapidly decrease in peritoneal effluents from PD
patients after initiation of antibiotic therapy. Mean 6 SEM.
Clinical data in table 1. *p,0.002 vs day 1. B) Scatter plot
showing the negative correlation between sTWEAK levels and the
number of peritoneal neutrophils in peritoneal effluents during 17
episodes of peritonitis in PD patients.
(TIF)
Figure S2 TWEAK induces transient neutrophil recruit-
ment in murine peritoneal effluents. Quantification by flow
cytometry of neutrophils present in murine peritoneal lavage.
Mean 6 SEM of 5 animals per group. *p,0.008 vs control.
Neutrophils were defined as Gr1+/F4/802cells.
(TIF)
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